<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318977</url>
  </required_header>
  <id_info>
    <org_study_id>19-1616-101</org_study_id>
    <nct_id>NCT04318977</nct_id>
  </id_info>
  <brief_title>rTMS Add on Value for Amelioration of Negative Symptoms of Schizophrenia</brief_title>
  <acronym>RADOVAN</acronym>
  <official_title>rTMS Add on Value for Amelioration of Negative Symptoms of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Aachen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brno University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Regensburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of depression with repetitive transcranial magnetic stimulation (rTMS) has shown
      high evidence using high-frequency left dorsolateral prefrontal cortex (DLPFC) stimulation.
      The treatment of negative symptoms with the same protocol in schizophrenia is considered as
      possible effective. Theta burst stimulation is a new protocol which is characterized by
      shorter sessions showing first evidence that it's efficacy is comparable to the
      high-frequency rTMS. In this randomized placebo-controlled study the efficacy of
      high-frequency rTMS and TBS are evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this randomized placebo-controlled study the efficacy of high-frequency rTMS and TBS are
      evaluated. The active study arms are high-frequency rTMS and iTBS of the left dorsolateral
      prefrontal cortex to treat negative symptoms in schizophrenia. The control arm will include
      the same number of patients as each active arm and includes both sham rTMS and sham iTBS in
      the same proportion as the active treatments.

      Standards of the trial will be harmonized across four clinical centers with the aim to pool
      data for analysis. Each center is responsible for ethical approval and adherence to good
      clinical practice by itself (Sponsor).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled trial with two active and one placebo arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scale for the Assessement of Negative Symptoms (SANS)</measure>
    <time_frame>4 weeks</time_frame>
    <description>negative symptoms in schizophrenia with 25 items and a range 0-125 with higher score representing more symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scale for the Assessement of Negative Symptoms (SANS)</measure>
    <time_frame>2 weeks, 4 weeks, 12 weeks</time_frame>
    <description>negative symptoms in schizophrenia with 25 items and a range 0-125 with higher score representing more symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative syndrome scale (PANSS)</measure>
    <time_frame>2 weeks, 4 weeks, 12 weeks</time_frame>
    <description>positive and negative symptoms in schizophrenia with 30 items and a range 30-210 with higher scores representing more symptoms (total score, score for positive, negative symptoms and for general psychopathology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calgary Depression Scale for Schizophrenia (CDSS)</measure>
    <time_frame>2 weeks, 4 weeks, 12 weeks</time_frame>
    <description>Calgary Depression Scale for Schizophrenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical global impression (CGI)</measure>
    <time_frame>2 weeks, 4 weeks, 12 weeks</time_frame>
    <description>measure of overall symptom severity and treatment response on a scale 1-7 with higher scores presenting more symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Depression Inventory (MDI)</measure>
    <time_frame>2 weeks, 4 weeks, 12 weeks</time_frame>
    <description>measurment of depressivity: 10 items with a range 0-50 and higher values indicating higher scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton depression rating scale (HDRS)</measure>
    <time_frame>2 weeks, 4 weeks, 12 weeks</time_frame>
    <description>measurment of depressivity: 21 items with a range 0-65 and higher values indicating higher scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Memory span test (digit span)</measure>
    <time_frame>4 weeks, 12 weeks</time_frame>
    <description>test for short-term and working memory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>test of attention (d2)</measure>
    <time_frame>4 weeks, 12 weeks</time_frame>
    <description>test of attention for measurement of concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting state electroencephalogram (EEG)</measure>
    <time_frame>4 weeks</time_frame>
    <description>measurement of resting state electrophysiologic activity as indicated by frequency analysis and rTMS-evoked activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>magnetic resonance imaging (MRI)</measure>
    <time_frame>4 weeks</time_frame>
    <description>structural, anatomical, diffusion weighted magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cigarettes</measure>
    <time_frame>4 weeks, 12 weeks</time_frame>
    <description>number of smoked cigarettes per week</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Negative Symptoms With Primary Psychotic Disorder</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>high-frequency repetitive transcranial magnetic stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>repetitive transcranial magnetic stimulation over left dorsolateral prefrontal cortex using 3000 pulses applied with 10Hz and 120% resting motor threshold</description>
  </arm_group>
  <arm_group>
    <arm_group_label>theta burst stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intermittent theta burst stimulation over left dorsolateral prefrontal cortex using 600 pulses applied in trains of 10 triplets/bursts (50Hz) with 8s intertrain-interval and 120% resting motor threshold</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham rTMS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>half of the patients with high-frequency repetitive transcranial magnetic stimulation and half of the patients with theta burst Stimulation with angled coil (45 degree) or sham coil</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>high-frequency rTMS</intervention_name>
    <description>repetitive transcranial magnetic stimulation</description>
    <arm_group_label>high-frequency repetitive transcranial magnetic stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TBS</intervention_name>
    <description>theta burst stimulation</description>
    <arm_group_label>theta burst stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo transcranial magnetic stimulation</description>
    <arm_group_label>sham rTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ICD-10: schizophrenia with primarily negative symptoms

          -  Age: 18-75 years

          -  at least 35 Points at the composite score of the SANS

          -  stabe medication during the last 2 weeks (at the investigator's discretion)

          -  written informed consent (by the patient or guardian)

        Exclusion Criteria:

          -  clinically relevant unstable concomitant somatic diseases

          -  previous treatment by rTMS

          -  conditions in which TMS may not be applicated, as e.g., cardiac pacemakers or
             ferromagnetic implants

          -  history of epileptic seizures

          -  current substance or alcohol abuse, or clinically relevant comorbidity (according to
             M.I.N.I. interview)

          -  unacceptable concomitant medication (benzodiazepines in higher doses, e.g., Lorazepam
             &gt; 2 mg/d, Diazepam &gt; 10 mg/d)

          -  insufficient knowledge of the language of the country of the treatment site

          -  pregnancy and nursing period

          -  current statutory hospitalisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Berthold Langguth, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Regensburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tobias Hebel, MD</last_name>
    <phone>+49-941-941-1250</phone>
    <email>tobias.hebel@medbo.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Schecklmann, PhD</last_name>
    <phone>+49-941-941-1250</phone>
    <email>martin.schecklmann@medbo.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brno University Hospital</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Libor Ustohal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Skront</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timm Pöppl</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Hebel, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Regensburg</investigator_affiliation>
    <investigator_full_name>Berthold Langguth, MD, Ph.D.</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

